Molecular analysis of different FLT3-ITD mutations in acute myeloid leukemia

Leukemia and Lymphoma

Volumn 54, Issue 1, 2013, Pages 145-152

  Blau, Olga ^a   Berenstein, Rimma ^b   Sindram, Annette ^a   Blau, Igor Wolfgang ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

AML; FLT3 ITD; FLT3 ITD mutant wild type ratio; FLT3 JMD; FLT3 TKD1

Indexed keywords

CD135 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CARBOXY TERMINAL SEQUENCE; CYTOGENETICS; FEMALE; GENE DUPLICATION; GENE MUTATION; HUMAN; INTERNAL TANDEM DUPLICATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ADOLESCENT; ADULT; AGED; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RETROSPECTIVE STUDIES; TANDEM REPEAT SEQUENCES; YOUNG ADULT;

EID: 84870877865     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.704999     Document Type: Article

References (36)

1. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336. (Pubitemid 35429670)
2. Mr ó zek K, Bloomfi eld C D. C hromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2006: 169-177.
3. Grimwade D, Hills RK, Moorman AV, et al.; National Cancer Research Institute Adult Leukaemia Working Group. Refi nement of cytogenetic classifi cation in acute myeloid leukemia: Determination of prognostic signifi cance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354- 365.
4. Estey E. High cytogenetic or molecular genetic risk acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2010: 474- 480.
5. B aldus C, M rozek K, M arcucci G, et al. C linical outcome of de novo acute myeloid leukemia patients with normal cytogenetics is aff ected by molecular genetic alterations: A concise review. Br J Haematol 2007 ; 137: 387-400. (Pubitemid 46698282)
6. B acher U, S chnittger S, H aferlach C, et al. M olecular diagnostics in acute leukemias. Clin Chem Lab Med 2009 ; 47: 1333-1341.
7. D ö hner K, D ö hner H. Molecular characterization of acute myeloid leukemia. Haematologica 2008; 93: 976- 982. (Pubitemid 351957013)
8. G aidzik V, D ö h ner K. P rognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 2008 ; 35: 346-355.
9. Marcucci G, Hafelach T, D ö hner H. Molecular genetics of adult acute myeloid leukemia: Prognostic and therapeutic implications. J Clin Oncol 2011 ; 10: 475-486.
10. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the fi rst cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001 ; 98: 1752-1759.
11. Th iede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identifi cation of subgroups with poor prognosis. Blood 2002 ; 99: 4326-4335. (Pubitemid 34627197)
12. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic signifi cance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 2002; 100: 4372- 4380. (Pubitemid 35434129)
13. W hitman S P, A rcher K J, F eng L, et al. A bsence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer and Leukemia Group B study. Cancer Res 2001; 61: 7233- 7239. (Pubitemid 32946520)
14. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008 ; 111: 2776-2784.
15. McCormick SR, McCormick MJ, Grutkoski PS, et al. FLT3 mutations at diagnosis and relapse in acute myeloid leukemia: Cytogenetic and pathologic correlations, including cuplike blast morphology. Arch Pathol Lab Med 2010; 134: 1143- 1151.
16. A bu-Duhier F M, G oodeve A C, W ilson G A, et al. I dentifi cation of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001 ; 113: 983-988. (Pubitemid 32634768)
17. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001 ; 97: 2434-2439. (Pubitemid 32291491)
18. Griffith J, Black J, Faerman C, et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 2004 ; 13: 169-178. (Pubitemid 38183264)
19. Sitnicka E, B uza-Vidas N, L arsson S, et al. H uman CD34 hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express fl t3: Distinct fl t3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells. Blood 2003 ; 102: 881-886. (Pubitemid 36917779)
20. Srinivasa SP, Doshi PD. Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line. Leukemia 2002 ; 16: 244-253. (Pubitemid 34145142)
21. Zhang S, Fukuda S, Lee Y, et al. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med 2000; 192: 719- 728.
22. Adolfsson J, Borge OJ, Bryder D, et al. Upregulation of Flt3 expression within the bone marrow Lin(-)Sca1 (-) c-kit (-) stem cell compartment is accompanied by loss of self-renewal capacity. Immunity 2001 ; 15: 659-669. (Pubitemid 33016450)
23. Rocnik J, Okabe R, Yu JC, et al. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood 2006 ; 108: 1339-1345. (Pubitemid 44232034)
24. Mr ó zek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classifi cation? Blood 2007; 109: 431- 448. (Pubitemid 46105936)
25. Schlenk RF, D ö hner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008 ; 358: 1909-1918. (Pubitemid 351620111)
26. B retenbuecher F, S hnittger S, G rundler R, et al. I dentification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood 2008 ; 113: 4074-4077.
27. Kayser S, Schlenk RF, Londono MC, et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood 2009 ; 114: 2386-2392.
28. Meshinchi S, Stirewalt D, Alonzo TA, et al. Structural and numerical variation of FLT3/ITD in pediatric AML. Blood 2008 ; 111: 4930-4933.
29. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. Size of FLT3 internal tandem duplication has prognostic signifi cance in patients with acute myeloid leukemia. Blood 2006 ; 107: 3724-3726.
30. Kusec R, Jaksic O, Ostojic S, et al. More on prognostic signifi cance of FLT3/ITD size in acute myeloid leukemia (AML). Blood 2006 ; 108: 405-406. (Pubitemid 43990662)
31. P onziani V, G ianfaldoni G, M annelli F, et al. The size of duplication does not add to the prognostic signifi cance of FLT3 internal tandem duplication in acute myeloid leukemia patients. Leukemia 2006 ; 20: 2074-2076. (Pubitemid 44614912)
32. Vempati S, Reindl C, Kaza SK, et al. Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential. Blood 2007 ; 110: 686-694. (Pubitemid 47105408)
33. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990 ; 8: 813-819. (Pubitemid 20148273)
34. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol 1991 ; 9: 191-192.
35. Kiyoi H, Naoe T, Yokota S, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia: Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 1997 ; 11: 1447-1452. (Pubitemid 27404383)
36. Griffiths M, Mason J, Rindl M, et al. Acquired isodisomy for chromosome 13 is common in AML, and associated with FLT3-itd mutations. Leukemia 2005 ; 19: 2355-2358. (Pubitemid 41741640)